Corey J. Langer

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-206
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-5121
Fax: 215-615-5122
Lab: CP 215-806-6152
Education:
B.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Permanent link
 

Description of Itmat Expertise

Thoracic and Head and Neck Oncology. Combined Modality Therapy: integration of radiation and systemic therapy. Targeted and Personalized Cancer Therapeutics.

Selected Publications

Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V.: Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 Nov;125:273-281. 125: 273-281, November 2018.

Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S. : Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. Lung Cancer. 2017 Oct;112:118-125. October 2018.

Hirsh V, Wan Y, Lin FJ, Margunato-Debay S, Ong TJ, Botteman M, Langer C.: Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. Clin Lung Cancer. 2018 Sep;19(5):401-409. September 2018.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.: Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 Sep 10;36(26):2693-2701. September 2018.

Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. : Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist. 2018 Aug;23(8):891-899. August 2018.

Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, Nachiappan AC, Simone CB 2nd, Langer CJ.: Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Jul;13(7):978-986. July 2018.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, PĂ©rol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.: Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 Jul;19(4):331-339. July 2018.

Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, Nachiappan AC, Simone CB 2nd, Langer CJ. : Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Jul;13(7):978-986. July 2018.

Langer CJ, Kim ES, Anderson EC, Jotte RM, Modiano M, Haggstrom DE, Socoteanu MP, Smith DA, Dakhil C, Konduri K, Berry T, Ong TJ, Sanford A, Amiri K, Goldman JW, Weiss J; ABOUND.70+ Investigators.: nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Front Oncol. 2018 Jul 24;8:262. July 2018.

Bonomi P, Blumenthal G, Ferris AS, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A.: Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. J Thorac Oncol. 2018 Jun;13(6):748-751. June 2018.

back to top
Last updated: 11/28/2018
The Trustees of the University of Pennsylvania